A Consensus Molecular Classification of Muscle-invasive Bladder Cancer

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. / Kamoun, Aurélie; de Reyniès, Aurélien; Allory, Yves; Sjödahl, Gottfrid; Robertson, A. Gordon; Seiler, Roland; Hoadley, Katherine A.; Groeneveld, Clarice S.; Al-Ahmadie, Hikmat; Choi, Woonyoung; Castro, Mauro A.A.; Fontugne, Jacqueline; Eriksson, Pontus; Mo, Qianxing; Kardos, Jordan; Zlotta, Alexandre; Hartmann, Arndt; Dinney, Colin P.; Bellmunt, Joaquim; Powles, Thomas; Malats, Núria; Chan, Keith S.; Kim, William Y.; McConkey, David J.; Black, Peter C.; Dyrskjøt, Lars; Höglund, Mattias; Lerner, Seth P.; Real, Francisco X.; Radvanyi, François; The bladder Cancer Molecular Taxonomy Group.

I: European Urology, Bind 77, Nr. 4, 04.2020, s. 420-433.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Kamoun, A, de Reyniès, A, Allory, Y, Sjödahl, G, Robertson, AG, Seiler, R, Hoadley, KA, Groeneveld, CS, Al-Ahmadie, H, Choi, W, Castro, MAA, Fontugne, J, Eriksson, P, Mo, Q, Kardos, J, Zlotta, A, Hartmann, A, Dinney, CP, Bellmunt, J, Powles, T, Malats, N, Chan, KS, Kim, WY, McConkey, DJ, Black, PC, Dyrskjøt, L, Höglund, M, Lerner, SP, Real, FX, Radvanyi, F & The bladder Cancer Molecular Taxonomy Group 2020, 'A Consensus Molecular Classification of Muscle-invasive Bladder Cancer', European Urology, bind 77, nr. 4, s. 420-433. https://doi.org/10.1016/j.eururo.2019.09.006

APA

Kamoun, A., de Reyniès, A., Allory, Y., Sjödahl, G., Robertson, A. G., Seiler, R., Hoadley, K. A., Groeneveld, C. S., Al-Ahmadie, H., Choi, W., Castro, M. A. A., Fontugne, J., Eriksson, P., Mo, Q., Kardos, J., Zlotta, A., Hartmann, A., Dinney, C. P., Bellmunt, J., ... The bladder Cancer Molecular Taxonomy Group (2020). A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. European Urology, 77(4), 420-433. https://doi.org/10.1016/j.eururo.2019.09.006

CBE

Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, Castro MAA, Fontugne J, Eriksson P, Mo Q, Kardos J, Zlotta A, Hartmann A, Dinney CP, Bellmunt J, Powles T, Malats N, Chan KS, Kim WY, McConkey DJ, Black PC, Dyrskjøt L, Höglund M, Lerner SP, Real FX, Radvanyi F, The bladder Cancer Molecular Taxonomy Group. 2020. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. European Urology. 77(4):420-433. https://doi.org/10.1016/j.eururo.2019.09.006

MLA

Vancouver

Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R o.a. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. European Urology. 2020 apr;77(4):420-433. https://doi.org/10.1016/j.eururo.2019.09.006

Author

Kamoun, Aurélie ; de Reyniès, Aurélien ; Allory, Yves ; Sjödahl, Gottfrid ; Robertson, A. Gordon ; Seiler, Roland ; Hoadley, Katherine A. ; Groeneveld, Clarice S. ; Al-Ahmadie, Hikmat ; Choi, Woonyoung ; Castro, Mauro A.A. ; Fontugne, Jacqueline ; Eriksson, Pontus ; Mo, Qianxing ; Kardos, Jordan ; Zlotta, Alexandre ; Hartmann, Arndt ; Dinney, Colin P. ; Bellmunt, Joaquim ; Powles, Thomas ; Malats, Núria ; Chan, Keith S. ; Kim, William Y. ; McConkey, David J. ; Black, Peter C. ; Dyrskjøt, Lars ; Höglund, Mattias ; Lerner, Seth P. ; Real, Francisco X. ; Radvanyi, François ; The bladder Cancer Molecular Taxonomy Group. / A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. I: European Urology. 2020 ; Bind 77, Nr. 4. s. 420-433.

Bibtex

@article{233e2af57163410798b4ce8a7df936b8,
title = "A Consensus Molecular Classification of Muscle-invasive Bladder Cancer",
abstract = "Background: Muscle-invasive bladder cancer (MIBC) is a molecularly diverse disease with heterogeneous clinical outcomes. Several molecular classifications have been proposed, but the diversity of their subtype sets impedes their clinical application. Objective: To achieve an international consensus on MIBC molecular subtypes that reconciles the published classification schemes. Design, setting, and participants: We used 1750 MIBC transcriptomic profiles from 16 published datasets and two additional cohorts. Outcome measurements and statistical analysis: We performed a network-based analysis of six independent MIBC classification systems to identify a consensus set of molecular classes. Association with survival was assessed using multivariable Cox models. Results and limitations: We report the results of an international effort to reach a consensus on MIBC molecular subtypes. We identified a consensus set of six molecular classes: luminal papillary (24%), luminal nonspecified (8%), luminal unstable (15%), stroma-rich (15%), basal/squamous (35%), and neuroendocrine-like (3%). These consensus classes differ regarding underlying oncogenic mechanisms, infiltration by immune and stromal cells, and histological and clinical characteristics, including outcomes. We provide a single-sample classifier that assigns a consensus class label to a tumor sample's transcriptome. Limitations of the work are retrospective clinical data collection and a lack of complete information regarding patient treatment. Conclusions: This consensus system offers a robust framework that will enable testing and validation of predictive biomarkers in future prospective clinical trials. Patient summary: Bladder cancers are heterogeneous at the molecular level, and scientists have proposed several classifications into sets of molecular classes. While these classifications may be useful to stratify patients for prognosis or response to treatment, a consensus classification would facilitate the clinical use of molecular classes. Conducted by multidisciplinary expert teams in the field, this study proposes such a consensus and provides a tool for applying the consensus classification in the clinical setting. An international consortium of bladder cancer expert teams establishes a consensus reconciling the diverse molecular classifications of muscle-invasive bladder cancer. This work offers a robust framework that will enable testing and validating predictive biomarkers in future prospective clinical trials.",
keywords = "Consensus, Molecular taxonomy, Muscle-invasive bladder cancer, Transcriptomic classifier",
author = "Aur{\'e}lie Kamoun and {de Reyni{\`e}s}, Aur{\'e}lien and Yves Allory and Gottfrid Sj{\"o}dahl and Robertson, {A. Gordon} and Roland Seiler and Hoadley, {Katherine A.} and Groeneveld, {Clarice S.} and Hikmat Al-Ahmadie and Woonyoung Choi and Castro, {Mauro A.A.} and Jacqueline Fontugne and Pontus Eriksson and Qianxing Mo and Jordan Kardos and Alexandre Zlotta and Arndt Hartmann and Dinney, {Colin P.} and Joaquim Bellmunt and Thomas Powles and N{\'u}ria Malats and Chan, {Keith S.} and Kim, {William Y.} and McConkey, {David J.} and Black, {Peter C.} and Lars Dyrskj{\o}t and Mattias H{\"o}glund and Lerner, {Seth P.} and Real, {Francisco X.} and Fran{\c c}ois Radvanyi and {The bladder Cancer Molecular Taxonomy Group} and Ann Taber",
year = "2020",
month = apr,
doi = "10.1016/j.eururo.2019.09.006",
language = "English",
volume = "77",
pages = "420--433",
journal = "European Urology (Italian Edition)",
issn = "1828-6569",
publisher = "EdizioniEdra",
number = "4",

}

RIS

TY - JOUR

T1 - A Consensus Molecular Classification of Muscle-invasive Bladder Cancer

AU - Kamoun, Aurélie

AU - de Reyniès, Aurélien

AU - Allory, Yves

AU - Sjödahl, Gottfrid

AU - Robertson, A. Gordon

AU - Seiler, Roland

AU - Hoadley, Katherine A.

AU - Groeneveld, Clarice S.

AU - Al-Ahmadie, Hikmat

AU - Choi, Woonyoung

AU - Castro, Mauro A.A.

AU - Fontugne, Jacqueline

AU - Eriksson, Pontus

AU - Mo, Qianxing

AU - Kardos, Jordan

AU - Zlotta, Alexandre

AU - Hartmann, Arndt

AU - Dinney, Colin P.

AU - Bellmunt, Joaquim

AU - Powles, Thomas

AU - Malats, Núria

AU - Chan, Keith S.

AU - Kim, William Y.

AU - McConkey, David J.

AU - Black, Peter C.

AU - Dyrskjøt, Lars

AU - Höglund, Mattias

AU - Lerner, Seth P.

AU - Real, Francisco X.

AU - Radvanyi, François

AU - The bladder Cancer Molecular Taxonomy Group

AU - Taber, Ann

PY - 2020/4

Y1 - 2020/4

N2 - Background: Muscle-invasive bladder cancer (MIBC) is a molecularly diverse disease with heterogeneous clinical outcomes. Several molecular classifications have been proposed, but the diversity of their subtype sets impedes their clinical application. Objective: To achieve an international consensus on MIBC molecular subtypes that reconciles the published classification schemes. Design, setting, and participants: We used 1750 MIBC transcriptomic profiles from 16 published datasets and two additional cohorts. Outcome measurements and statistical analysis: We performed a network-based analysis of six independent MIBC classification systems to identify a consensus set of molecular classes. Association with survival was assessed using multivariable Cox models. Results and limitations: We report the results of an international effort to reach a consensus on MIBC molecular subtypes. We identified a consensus set of six molecular classes: luminal papillary (24%), luminal nonspecified (8%), luminal unstable (15%), stroma-rich (15%), basal/squamous (35%), and neuroendocrine-like (3%). These consensus classes differ regarding underlying oncogenic mechanisms, infiltration by immune and stromal cells, and histological and clinical characteristics, including outcomes. We provide a single-sample classifier that assigns a consensus class label to a tumor sample's transcriptome. Limitations of the work are retrospective clinical data collection and a lack of complete information regarding patient treatment. Conclusions: This consensus system offers a robust framework that will enable testing and validation of predictive biomarkers in future prospective clinical trials. Patient summary: Bladder cancers are heterogeneous at the molecular level, and scientists have proposed several classifications into sets of molecular classes. While these classifications may be useful to stratify patients for prognosis or response to treatment, a consensus classification would facilitate the clinical use of molecular classes. Conducted by multidisciplinary expert teams in the field, this study proposes such a consensus and provides a tool for applying the consensus classification in the clinical setting. An international consortium of bladder cancer expert teams establishes a consensus reconciling the diverse molecular classifications of muscle-invasive bladder cancer. This work offers a robust framework that will enable testing and validating predictive biomarkers in future prospective clinical trials.

AB - Background: Muscle-invasive bladder cancer (MIBC) is a molecularly diverse disease with heterogeneous clinical outcomes. Several molecular classifications have been proposed, but the diversity of their subtype sets impedes their clinical application. Objective: To achieve an international consensus on MIBC molecular subtypes that reconciles the published classification schemes. Design, setting, and participants: We used 1750 MIBC transcriptomic profiles from 16 published datasets and two additional cohorts. Outcome measurements and statistical analysis: We performed a network-based analysis of six independent MIBC classification systems to identify a consensus set of molecular classes. Association with survival was assessed using multivariable Cox models. Results and limitations: We report the results of an international effort to reach a consensus on MIBC molecular subtypes. We identified a consensus set of six molecular classes: luminal papillary (24%), luminal nonspecified (8%), luminal unstable (15%), stroma-rich (15%), basal/squamous (35%), and neuroendocrine-like (3%). These consensus classes differ regarding underlying oncogenic mechanisms, infiltration by immune and stromal cells, and histological and clinical characteristics, including outcomes. We provide a single-sample classifier that assigns a consensus class label to a tumor sample's transcriptome. Limitations of the work are retrospective clinical data collection and a lack of complete information regarding patient treatment. Conclusions: This consensus system offers a robust framework that will enable testing and validation of predictive biomarkers in future prospective clinical trials. Patient summary: Bladder cancers are heterogeneous at the molecular level, and scientists have proposed several classifications into sets of molecular classes. While these classifications may be useful to stratify patients for prognosis or response to treatment, a consensus classification would facilitate the clinical use of molecular classes. Conducted by multidisciplinary expert teams in the field, this study proposes such a consensus and provides a tool for applying the consensus classification in the clinical setting. An international consortium of bladder cancer expert teams establishes a consensus reconciling the diverse molecular classifications of muscle-invasive bladder cancer. This work offers a robust framework that will enable testing and validating predictive biomarkers in future prospective clinical trials.

KW - Consensus

KW - Molecular taxonomy

KW - Muscle-invasive bladder cancer

KW - Transcriptomic classifier

UR - http://www.scopus.com/inward/record.url?scp=85072635570&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2019.09.006

DO - 10.1016/j.eururo.2019.09.006

M3 - Journal article

C2 - 31563503

AN - SCOPUS:85072635570

VL - 77

SP - 420

EP - 433

JO - European Urology (Italian Edition)

JF - European Urology (Italian Edition)

SN - 1828-6569

IS - 4

ER -